Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was $91.7 million, representing a sequential growth of nearly 40% from $66 million in Q3 2025 [18] - Full year 2025 total net revenue reached $190.4 million, with a positive net income of $20.9 million, marking a significant turnaround from a net loss of $175.9 million in 2024 [24] - Cash from operating activities for Q4 was $48.7 million, and the company ended the year with over $506 million in cash equivalents and marketable securities [5][18] Business Line Data and Key Metrics Changes - VYKAT XR, the company's primary product, achieved 1,250 patient start forms since its launch, capturing approximately 12.5% of the U.S. addressable market for Prader-Willi syndrome (PWS) [7][12] - Active treatment numbers increased from 764 at the end of Q3 to 859 by the end of Q4, indicating successful adoption into clinical practice [12] - The cumulative launch-to-date discontinuation rate related to adverse events was approximately 12% as of the end of Q4, with an expected long-term discontinuation rate of 15%-20% [8][14] Market Data and Key Metrics Changes - The company is targeting approximately 9,500 individuals living with PWS in the UK and EU4, with a concentrated market driven by centers of excellence [10] - Coverage for VYKAT XR has expanded to over 180 million lives across various channels, including commercial, Medicaid, and Medicare [16] Company Strategy and Development Direction - The company plans to expand beyond PWS, with Glycogen Storage Disease Type I (GSD I) identified as a potential new indication for VYKAT XR [26] - The strategy includes deepening experience and adoption among key opinion leaders (KOLs) and broadening the prescriber base in community settings [15][67] - The company is also considering commercialization options in the EU, with a focus on building its own team and capabilities [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum for VYKAT XR, with strong leading indicators for growth [7] - The company anticipates a regulatory decision for DCCR in the EU by mid-2026, following the submission of responses to Day 120 questions [9][78] - Management highlighted the importance of real-world safety profiles and the positive feedback from caregivers and prescribers regarding VYKAT XR [8][14] Other Important Information - The company has a strong balance sheet, allowing for continued investment in commercialization and potential new indications [19] - Research and development expenses for Q4 were $9.6 million, significantly lower than the previous year, reflecting a strategic focus on commercialization [21][22] Q&A Session Summary Question: What is the expected cadence for the 1,000 patient start forms over the next 9-12 months? - Management indicated that the start forms will come in over the year rather than in a specific quarter [31][32] Question: What percentage of the market could be accessible for PWS in the U.S.? - Management suggested that a higher penetration than the typical 40%-50% could be expected due to the lack of existing treatments [37] Question: What are the refill rates and how might the average weight of new patients change over time? - Management reported high adherence rates and indicated that the average weight of new patients is expected to increase as more older patients are treated [41][42] Question: How does the company view exclusivity and patent prosecution for VYKAT XR? - Management confirmed ongoing efforts to extend exclusivity through additional patents, with some patents potentially extending into the late 2030s [71] Question: What are the expectations for the EU approval process? - Management expressed cautious optimism, noting that the nature of the key questions from the EMA focused on efficacy data [78]

Financial Data and Key Metrics Changes - Total net revenue for Q4 2025 was $91.7 million, representing a sequential growth of nearly 40% from $66 million in Q3 2025 [18] - Full-year 2025 total net revenue was $190.4 million, with a positive net income of $20.9 million and cash flow positive with $48.7 million generated from operating activities in Q4 [5][18] - The company ended the year with over $506 million in cash equivalents and marketable securities [5][18] Business Line Data and Key Metrics Changes - VYKAT XR received 1,250 patient start forms since its launch, capturing approximately 12.5% of the U.S. addressable market for Prader-Willi syndrome (PWS) [6][11] - Active treatment increased to 859 individuals by the end of Q4, up from 764 at the end of Q3 [11] - The cumulative launch-to-date discontinuation rate related to adverse events was approximately 12% as of the end of Q4, with an expected long-term discontinuation rate of 15%-20% [7][14] Market Data and Key Metrics Changes - The company anticipates capturing an additional approximately 1,000 patient start forms over the next nine to twelve months [6] - The U.K. and EU markets are estimated to have about 9,500 individuals living with PWS, with strong support from thought leaders for VYKAT XR [9] Company Strategy and Development Direction - The company plans to expand beyond PWS into other metabolic rare disease indications, starting with Glycogen Storage Disease Type I (GSD I) [26] - The strategy includes filing an IND for GSD I in the first half of 2026 and initiating a clinical program later that year [27] - The focus remains on successful commercialization of VYKAT XR in the U.S. and exploring opportunities in the EU and other geographies [64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum and capturing additional market share for VYKAT XR, highlighting strong engagement from prescribers and caregivers [6][12] - The management acknowledged the complexities of the PWS patient population and the importance of real-world safety profiles [7][14] - The company is optimistic about the upcoming regulatory decision in the EU and potential commercialization options [8][9] Other Important Information - The company has a strong balance sheet, ensuring sufficient capital for ongoing operations and potential new indications [19] - The CFO announced retirement plans, with a successor already identified to ensure a smooth transition [25] Q&A Session Summary Question: What is the expected cadence for the 1,000 patient start forms over the next nine to twelve months? - Management indicated that the start forms will come in over the year rather than in a specific quarter [31][32] Question: What percent of the market could be accessible in the U.S. for PWS? - Management suggested that higher penetration than 40%-50% is possible given the lack of other treatments [37] Question: What are the refill rates and how might the average weight of new patients change over time? - Management reported high adherence rates and expected that the average weight of new patients would likely increase over time [40][41] Question: How does the company view exclusivity and patent prosecution for VYKAT XR? - Management confirmed ongoing efforts to extend IP beyond current patents, with potential extensions into the late 2030s [68] Question: What are the expectations for the EU approval process? - Management noted that they are awaiting Day 180 questions from the EMA and are optimistic about the approval process despite challenges [75]

Group 1 - The overall industry is experiencing an upward trend, leading to full orders and high demand for products, prompting companies to maintain production during the Spring Festival to ensure timely delivery [1] - Zhejiang Yuntao Biotechnology Co., Ltd. is operating at full capacity to meet customer demands and is investing in a new project for an annual production of 4,000 tons of high-end fluorine fine chemicals [1] - The intelligent manufacturing platform at Taiding New Energy (Zhejiang) Co., Ltd. is running efficiently with automated systems, and the company has also started operations earlier during the Spring Festival to meet production and delivery schedules [1] Group 2 - The R&D center is actively working on refining research strategies and experimental plans, with a clear goal to achieve technological breakthroughs and results transformation as soon as possible [2]

Stock Performance - On February 24, 2026, the stock price of APLM.OQ (冠科美博) fell by 4.86% (or 4.88% according to different data sources), closing at $20.08. The trading volume was 6,453 shares, with a total transaction value of $129,743, and the stock experienced a volatility of 12.46% [1] - The biotechnology sector in the US stock market saw a slight decline of 0.07% on the same day, while major indices like the Nasdaq rose by 1.04%, indicating that APLM.OQ underperformed compared to both its sector and the broader market [1] Company Situation - There were no significant fundamental announcements from the company on that day, such as financial reports, clinical progress, or business collaborations [2] - The stock's price fluctuation may be attributed to market sentiment, as recent analyses indicated a widespread sell-off in US tech stocks, with concerns about capital returns in high-investment areas like AI affecting growth sectors, including biotechnology [2] - The trading characteristics of APLM.OQ showed a volume ratio of 0.58, indicating lower trading activity compared to recent averages, which may have amplified price volatility. The company's price-to-earnings (TTM) and price-to-book ratios were -0.75 and -9.79, respectively, reflecting a long-term loss situation that could heighten investor caution [2]

Core Viewpoint - GlaxoSmithKline has agreed to acquire Canadian biotech company 35Pharma for $950 million in cash, marking the second significant transaction under new CEO Luke Miels aimed at accelerating new drug development [1] Group 1: Acquisition Details - The acquisition price for 35Pharma is $950 million [1] - This transaction is part of GlaxoSmithKline's strategy to enhance its respiratory drug pipeline [1] Group 2: Strategic Implications - The experimental pulmonary hypertension drug HS235 from 35Pharma will strengthen GlaxoSmithKline's future respiratory drug offerings [1]

纳斯达克的市场定位主要体现在以下几个方面： （一）从企业规模与发展阶段角度 纳斯达克全球精选市场：定位为全球范围内的大盘蓝筹企业，是纳斯达克最高层次的市场。主要吸引已经发展成熟、具有强大实力和优秀业绩的大型企业， 如苹果、微软等科技巨头。其上市标准是三个层次中最高的，对公司的财务状况、市值、流动性等方面都有较高要求，旨在挑选出具有优秀业绩和强大实力 的公司。 纳斯达克市场以其独特的市场定位、鲜明的特征和多层次的上市标准，成为全球资本市场中璀璨的明珠。为科技创新企业提供了广阔的发展空间，为投资者 创造了丰富的投资机遇，也为全球经济的创新发展注入了强大动力。无论是对于寻求融资发展的企业，还是渴望获取高回报的投资者，纳斯达克市场都具有 不可抗拒的吸引力。在未来，随着科技的不断进步和全球经济的深入发展，纳斯达克有望继续发挥其独特优势，引领全球资本市场的创新与变革。本文将从 市场定位、特征以及上市标准等方面进行剖析。 ▍纳斯达克市场定位 纳斯达克以科技股为主导，是全球科技企业的主要融资平台之一，吸引了众多科技、互联网、生物医药等新兴行业的企业上市。这些行业具有高成长性、高 创新性和高风险性等特点，与纳斯达克市场对成长型 ...

Core Viewpoint - Salspera, a clinical-stage cancer biotechnology company focused on developing live biotherapeutics to stimulate immune responses, has announced its IPO terms, aiming to raise $85 million by issuing 5.7 million shares priced between $14 and $16 each [1] Company Overview - Salspera is headquartered in Cambridge, Massachusetts, and was founded in 2017 [1] - The company is developing a novel class of immunotherapy for solid tumors, referred to as "live biotherapeutics," which are genetically modified agents designed to express specific anti-tumor factors within the tumor microenvironment [1] Lead Project - The lead project, Saltikva, is a genetically modified strain of Salmonella typhimurium that is non-toxic and can be administered orally [1] - This engineered strain is designed to express the human interleukin-2 gene (Salmonella-IL2), potentially increasing the number of NK cells and CD8+ cytotoxic T cells in the tumor microenvironment and peripheral blood [1] - The company is currently focusing on pancreatic cancer and has completed a Phase II trial for patients with stage IV metastatic pancreatic cancer [1] IPO Details - Salspera plans to list on NASDAQ under the ticker symbol TKVA [1] - Kingswood Capital Markets is serving as the exclusive bookrunner for the transaction [1]

Core Viewpoint - The article highlights the innovative biomanufacturing technology developed by Professor Wei Dongzhi's team at East China University of Science and Technology, which allows for the production of high-purity squalene through genetically modified yeast, significantly reducing reliance on shark extraction methods [1][2]. Group 1: Biomanufacturing Technology - The new squalene manufacturing process can replace the extraction of 3,000 sharks with a single fermentation tank capable of producing 20 tons [1]. - The "multi-enzyme cooperative catalysis system" developed by the team has enabled the biomanufacturing of over 20 pharmaceutical and chemical products, serving as a "toolbox" for biobased product manufacturing [1][2]. - The team has created a large enzyme library with over 10,000 proprietary enzymes, facilitating efficient biomanufacturing processes [3]. Group 2: Technical Innovations - The team has developed a multi-enzyme cascade biocatalysis technology that allows different enzymes to work efficiently together, akin to building blocks with interlocking features [2]. - A significant breakthrough was achieved in the biomanufacturing of the herbicide L-phosphinothricin, with a production line capable of producing 10,000 tons annually, breaking foreign technology monopolies [6]. - The production line boasts nearly 100% raw material utilization and minimal wastewater discharge, with a significantly reduced footprint and investment compared to traditional chemical production lines [6]. Group 3: Industrial Impact - The team's research has led to the industrialization of over 100 technological achievements, empowering nearly 300 enterprises and generating over 150 billion yuan in economic value in the past three years [7]. - The successful industrial-scale production of pharmaceutical-grade squalene and nearly 100% raw material utilization in a million-ton citric acid production line exemplifies the team's contributions to the biomanufacturing sector [7]. - The research outcomes are being integrated into educational materials, emphasizing the importance of aligning scientific research with industrial needs [6][7].

此外，和铂医药还将获得最高11亿美元的里程碑付款，以及分级销售分成。公开资料显示，Solstice Oncology为一家多个头部风险投资机构联合创立的临床阶段生物技术公司，此次合作为NewCo模式。 和铂医药-B(02142)早盘涨超8%，截至发稿，涨7.92%，报13.21港元，成交额2179.47万港元。 消息面上，2月23日，和铂医药宣布将新一代CTLA-4抗体HBM4003大中华区外全球权益授权Solstice Oncology，后者支付逾1.05亿美元前期对价，包括5000万美元首付款，500万美元近期付款以及价值逾 5000万美元的公司股权。 ...

此外，和铂医药还将获得最高11亿美元的里程碑付款，以及分级销售分成。公开资料显示，Solstice Oncology为一家多个头部风险投资机构联合创立的临床阶段生物技术公司，此次合作为NewCo模式。 智通财经APP获悉，和铂医药-B(02142)早盘涨超8%，截至发稿，涨7.92%，报13.21港元，成交额 2179.47万港元。 消息面上，2月23日，和铂医药宣布将新一代CTLA-4抗体HBM4003大中华区外全球权益授权Solstice Oncology，后者支付逾1.05亿美元前期对价，包括5000万美元首付款，500万美元近期付款以及价值逾 5000万美元的公司股权。 ...